Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Astellas Shuts U.S./EU Phase III Diabetes Trial But Resumes Asia Development For Differentiated Markets

This article was originally published in The Pink Sheet Daily

Executive Summary

Astellas’ multi-track R&D approach leaves door open for a Western partner interested in a Phase III SGLT2 inhibitor, but the Japanese pharma’s main interest is finding ipragliflozin’s niche in Asia.


Related Content

Bristol Signals Dapaglifozin’s Back On Track, Plans FDA Resubmission
Astellas Outlicenses Products To California Startup, Considers Expanding Model To More Of Its Portfolio


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts